Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

Teva Pharmaceuticals USA is the leading generic pharmaceutical company, marketing products from a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, oncolytic, antidiabetic, analgesic, dermatology, respiratory, and women's healthcare. Dosage forms include tablets and capsules, injectables, creams, ointments, inhalants, solutions, and suspensions. Teva USA products are marketed to chains, wholesalers, distributors and government agencies, as well as in health systems and oncology settings. Teva USA has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry. The company's mission is to play a leading role in the transformation of the U.S. healthcare system through its pre-eminence in the development, manufacture and marketing of generic pharmaceuticals.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Life sciences researchers go shopping for molecules at Research and Diagnostic Systems The company (aka R&D Systems) is the primary subsidiary of TECHNE and manufactures and sells the tools used in life sciences research. Its biotechnology division offers thousands of proteins, antibodies, stem cells, and other handy stuff for researchers. Its BiosPacific subsidiary supplies biological ingredients to makers of in vitro diagnostic kits. R&D Systems' hematology division sells the blood components and equipment used to calibrate blood analysis equipment. Clients include pharmaceutical and biotechnology companies and academic and institutional research facilities.

TargeGen is developing small molecule therapeutics to treat cancer and cardiovascular disease. The development-stage firm's lead drug candidate, TG 100-115, could prevent complications after heart attacks. Other therapies in TargeGen's pipeline include a potential treatment for colorectal cancer, non-small cell lung cancer, and macular degeneration, an eye condition that often leads to blindness. The biotech company had been eying an IPO but opted in mid-2005 to stay private and took on an additional round of venture capital financing to fund trials of TG 100-115.

Neos Therapeutics makes generic drugs take their time. The contract pharmaceutical manufacturer develops and manufactures branded and generic prescription and OTC pharmaceuticals with an emphasis on time-released formulations. Its products include cold and cough remedies and nutritional supplements. Customers are primarily pharmaceutical distributors and other manufacturers. Neos Therapeutics was slapped hard by the FDA in 2007 for manufacturing unapproved drugs. The action prompted a change in ownership and the company was required to re-file its drug applications in order to resume manufacturing.

RXi Pharmaceuticals was founded in 2003 and is based in Worcester, Massachusetts. RXi Pharmaceuticals Corporation, a discovery-stage biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on RNA interference for the treatment of human diseases in the United States and internationally. It intends to identify lead compounds and advance towards pre-clinical and clinical development programs in various therapeutic areas, including inflammatory disease; and metabolic diseases, such as obesity and obesity-related type 2 diabetes. The company was formerly known as Argonaut Pharmaceuticals, Inc. and changed its name to RXi Pharmaceuticals Corporation in 2006 before beginning operations in 2007.

Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. Anacor also has a portfolio of other topical product candidates in development for the treatment of psoriasis, atopic dermatitis and skin and nail fungal infections. The company has entered into a worldwide license, development and commercialization agreement with Merck for the development and commercialization of AN2690 for all indications including the treatment of onychomycosis. In addition, Anacor has a research and development agreement with GSK for novel antiviral and antibacterial systemic therapeutics.

EastPharma would like to be the place where east meets west. The Turkish pharmaceutical manufacturer operates via two major subsidiaries. Deva Holdings makes branded generics, active pharmaceutical ingredients (API), veterinary products, and consumer hygiene products. Its Saba unit makes generic high-end cardiovascular and pain medications. EastPharma sells about 70 branded generics and a dozen licensed drugs including versions of the blockbuster drugs Viagra, Singulair, and Lamisil. The company operates seven manufacturing plants in and around Istanbul and sell its products in nearly 20 Eastern European countries with an eye toward Western expansion.

Skystar Bio-pharmaceutical Company ("Skystar") is one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. Skystar has over 173 products in its current product line and has over 50 more products in development. Skystar employs over 200 people in Production Facilities located in Hu Xian, Xi'an City, Shaanxi, Province, PRC.Skystar has recently opened (July of 2006) its new GMP Certified Facility that will increase production capabilities by 200%. The demand for veterinary medicines and vaccines in China far exceeds the supply and Skystar's plan is to capitalize on its new GMP Certified Facility to increase margins while increasing production to help meet the growing and overwhelming demand for its products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.